Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I PK, Safety, and Immunogenicity Study of CMAB015 vs Cosentyx in Healthy Male Subjects
NCT07254325Phase 1Completed
- Sponsor
- Taizhou Mabtech Pharmaceutical
- Start
- Dec 2025
- Primary completion
- Jun 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of secukinumab in psoriasis (2 arms), sponsored by Taizhou Mabtech Pharmaceutical. Primary endpoints: Area Under the Plasma Concentration-time Curve From Zero (0) Hours Extrapolated to infinite time at 2688 hours and Maximum Concentration of Secukinumab at 2688 hours. Started Dec 2025; status: completed.
02
Drugs
secukinumab
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT07254325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07254325.